<DOC>
	<DOCNO>NCT00541710</DOCNO>
	<brief_summary>The purpose study determine whether phytoestrogen genistein effective improve bone condition pre-menopausal post-menopausal woman suffer osteopenia . Since , study investigator realize least 70 % post-menopausal recruited woman suffer metabolic syndrome ( MS ) , add woman , secondary outcome measure , evaluation marker cardiovascular risk .</brief_summary>
	<brief_title>Effect Genistein Women With Metabolic Syndrome</brief_title>
	<detailed_description>MS prevalence increase onset menopause , estrogen deficiency . It still clear menopause increase risk cardiovascular disease al woman develop MS . Many MS patient show slight modification cardiovascular metabolic parameter generally pharmacologically treat since diabetes alteration lipid profile evidence . In respect importance develop new therapeutic strategy prevent treat MS. Genistein ( 4,5,7-trihydroxyisoflavone ) , show potentially preventive role cardiovascular apparatus post-menopausal woman , may term selective ER modulator ( SERM ) , since reveals ER-alpha full agonist ER-beta partial agonist activity . The investigator study whether genistein may represent efficacious safe alternative reduce vascular risk postmenopausal woman metabolic syndrome . The clinical study randomize , double-blind , placebo-controlled study involve 150 patient metabolic syndrome . After 4-week stabilization standard fat-reduced diet , participant randomly assign receive either phytoestrogen genistein ( 54 mg/day ) placebo 6 month . At baseline follow treatment fast plasma glucose , insulin , insulin resistance ( HOMA-IR ) , lipid concentration , plasma total homocysteine , leptin , adiponectin visfatin measure . Bioimpedentiometric nutritional analysis , well safety assessment endometrium vagina also perform .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Genistein</mesh_term>
	<criteria>Postmenopausal satus The presence three five follow criterion : waist circumference ≥88 cm ; Triglycerides ≥150 mg/dl drug treatment elevate triglyceride ; highdensitylipoprotein ( HDL ) cholesterol &lt; 50 mg/dl drug treatment reduce HDLC ; Fasting glucose ≥100 mg/dl drug treatment elevate glucose ; Blood pressure ≥130/85 mmHg antihypertensive drug treatment subject history hypertension . clinical laboratory evidence confound systemic disease ( e.g. , chronic renal hepatic failure , chronic inflammatory disease ) cardiovascular disease ( CVD ) define document myocardial infarction , ischaemic heart disease , coronary heart bypass , coronary angioplasty , cerebral thromboembolism , peripheral amputation , Minnesota cod 1°13 , 4°14 , 5°13 standard ECG perform 12 month precede study ; coagulopathy ; use oral transdermal estrogen , progestin , androgen , selective estrogen receptor modulators , steroid ; treatment precede six month polyunsaturated n3 fatty acid supplement , non steroidal antiinflammatory drug ( NSAIDs ) steroid , would interfere evaluation study medication ; smoke habit 2 cigarette daily .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>menopause</keyword>
	<keyword>genistein</keyword>
	<keyword>pre-diabetes</keyword>
</DOC>